ATC CODE P01AX07

TRIMETREXATE

A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against …

Φαρμακολογικό Προφίλ

Πηγή: DrugBank

Περιγραφή & Ένδειξη

A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. [PubChem]

Κύρια Ένδειξη

For use, with concurrent leucovorin administration (leucovorin protection), as an alternative therapy for the treatment of moderate-to-severe <i>Pneumocystis carinii</i> pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS). Also used to treat several types of cancer including colon cancer.

Χρόνος Ημιζωής

11to20h

11 to 20 hours

Σύνδεση Πρωτεϊνών

95% (over the concentration range of 18.75 to 1000 ng/mL)

Δείτε αναλυτικό φαρμακολογικό προφίλ.

+ Περισσότερες Φαρμακολογικές Πληροφορίες

Μηχανισμός Δράσης

In vitro studies have shown that trimetrexate is a competitive inhibitor of dihydrofolate reductase (DHFR) from bacterial, protozoan, and mammalian …

Οδός Αποβολής

Ten to 30% of the administered dose is excreted unchanged in the urine.

Όγκος Κατανομής

* 20 ± 8 L/m2 * 36.9 ± 6 L/m2 [cancer patients]

Κατηγορίες ATC

Βρείτε τη δραστική μέσα από τις αντίστοιχες κατηγορίες ATC level 5.

ATC Level 5

P01AX07

trimetrexate

›

Διαθέσιμα Σκευάσματα

Εγκεκριμένα φαρμακευτικά σκευάσματα που περιέχουν TRIMETREXATE.

Φόρτωση σκευασμάτων...

TRIMETREXATE Trimetrexate